Search results
The Generics Are Here: How Bristol Myers Squibb Expects Patent Losses To Hit In 2022
Investor's Business Daily· 2 years agoBristol Myers Squibb reaffirmed expectations for a $10 billion pitfall from its generics-facing...
Biden targets diabetes drug Jardiance, blood thinner Eliquis, and 8 others for controversial...
Fortune via Yahoo Finance· 9 months agoThe move is expected to cut costs in a few years for some patients but faces litigation from the...
Is prescription copay assistance contributing to rising drug prices? Why buyers should beware.
USA TODAY via Yahoo Finance· 2 years agoWhen Beth Waldron got a letter from her health insurance provider last year that her blood thinner...
Bristol Myers looks to new CEO as competition from generic drugs heats up
Reuters via Yahoo Finance· 1 year ago(Reuters) -Bristol Myers Squibb said on Wednesday evening its CEO Giovanni Caforio would step down...
Bayer ends large blood thinner trial for ‘inferior efficacy’
BioPharma Dive via Yahoo Finance· 6 months agoBayer is stopping a large clinical trial testing its experimental blood thinner asundexian in people...
These 10 Drugs Should Save Medicare Patients Millions After Price Negotiations
Verywell Health via Yahoo News· 9 months agoFor the first time, the federal government will negotiate with drug makers in order to reduce the...
Bristol-Myers (BMY) Q4 Earnings & Sales Beat, Stock Gains
Zacks via Yahoo Finance· 4 months agoBristol-Myers Squibb Company BMY reported better-than-expected results for the fourth quarter of...
Bristol-Myers (BMY) Q2 Earnings, Sales Miss, '23 View Lowered
Zacks via Yahoo Finance· 10 months agoBristol-Myers' (BMY) second-quarter 2023 earnings and sales miss estimates due to generic erosion...
Bristol Myers Relies On 'Mature' Products For Narrow Quarterly Beat
Investor's Business Daily· 2 years agoMost of Bristol Myers Squibb's "mature" products delivered commanding third-quarter performances, an...
Will Eliquis, Opdivo Fuel Bristol-Myers (BMY) Q3 Earnings?
Zacks via Yahoo Finance· 2 years agoInvestors are likely to focus on the demand for Eliquis and Opdivo along with an incremental...